[Value-based medicine for glaucoma].
The application of value-based medicine (VBM) tenets in the area of glaucoma research requires valid and reliable data concerning the quality of life with glaucoma. A multitude of instruments for measuring quality of life of patients with glaucoma have been employed in the past. Any instrument used would need to capture peripheral vision loss and its influence on patient-reported quality of life as this is one of the hallmarks of this disease. Cost-utility analyses can then be based on the reported quality of life and the cost of glaucoma therapy. Several cost-utility analyses have been applied in the field of glaucoma screening as well as treating ocular hypertension and based on this a recommendation regarding population subgroups which can be treated cost efficiently can be made.
Hirneiss
C
C
Augenklinik der Ludwig-Maximilians-Universität, München, Deutschland. Christoph.Hirneiss@med.uni-muenchen.de
Kampik
A
A
Neubauer
A S
AS
D003362:Cost-Benefit Analysis / Q000191:economics; D019317:Evidence-Based Medicine / Q000191:economics; D005858:Germany; D005901:Glaucoma / Q000191:economics* / Q000523:psychology / Q000628:therapy; D006801:Humans; D008390:Markov Chains; D008962:Models, Theoretical; D009313:National Health Programs / Q000191:economics*; D011788:Quality of Life / Q000523:psychology*; D015895:Relative Value Scales